Sp1072
IMPLEMENTATION OF SCREENING FOR BARRETT'S ESOPHAGUS - WHAT WILL IT TAKE?
Date
May 21, 2024
Explore related products in the following collection:
Presenter
Tracks
Related Products
CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES A PRO-STEATOTIC AND PRO-INFLAMMATORY METABOLIC STATE IN LIVER
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…
MODELLING FROM A MULTICENTRE, PRAGMATIC, RANDOMISED CONTROLLED TRIAL IDENTIFIES THE TARGET SCREENING POPULATION AND EXPECTED YIELD FOR BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER DIAGNOSES
Screening for Barrett’s esophagus (BE) could lead to earlier detection and improved survival of esophageal adenocarcinoma (EAC)…
BIOMARKER RISK STRATIFICATION USING THE CAPSULE SPONGE FOR THE SURVEILLANCE OF BARRETT'S ESOPHAGUS: INTERIM RESULTS FROM THE UK REAL-WORLD IMPLEMENTATION PILOTS.
Endoscopic surveillance is recommended for Barrett’s esophagus (BE), but the effectiveness is questionable and varies according to expertise. Pan-oesophageal cell collection devices with biomarkers offer a less operator dependent alternative…
